LATEST NEWS
CHIMES trial completed inclusion in May and all the sites are following up on the last few patients.
Moleac is happy to announce the launch of a representative office in Krakow (Poland) to orchestrate the operations in Eastern Europe, CIS and Balkans.
Our presence worldwide
Today we have 40 employees,12 nationalities, and operations throughout several countries.
Moleac’s Multi-Modal Approach to Treatment for Brain Injuries
Advances in research in the field of brain injury, like stroke, trauma and global ischemia, has never been more exciting and encouraging for the prospect of discovering novel effective treatments.
The conventional approach to research in acute treatment to develop one molecule targeted at one specific process in the pathway of one particular disease has failed in many consecutive clinical trials Moleac takes on a multi-model strategy in its approach to drug development.
Learn more
NeuroAiD
Moleac has brought to market the first drug that helps patients recover faster and better from their stroke disabilities.
NeuroAiD™ (MLC 601, MLC 901) addresses these gaps in pharmacological modalities which combined to a rehabilitation program offers new hopes to patients who had no other choice than to cope with their disabilities.
Learn more
Follow Us!
Upcoming events
18th–21st March, 2013 Moleac presenting at BioPharma Asia Convention
28th–31st May, 2013 European Stroke Conference London, United Kingdom
21st–26th September, 2013 World Congress of Neurology Vienna, Austria
Career Opportunities
If you are talented and ready for a new challenge, discover what Moleac has to offer you.
Find out about opportunities at Moleac
 |
Farewell Prof Marc Vasseur Marc Vasseur, founder and Chairman of the Board of Moleac, passed away on May 3rd 2013 aged 63. Marc started his career as a professor of virology at the University of Paris and taught at many other universities worldwide. After working for 10 years at the Pasteur Institute, a foundation for research and public health in Paris, Marc became director of biological research at L’Oreal. In 1989, he co-founded Genset and served as a Board Member, Chief Biology Officer and General Manager of the company until 2000. He left Genset in July 2000 and joined the company again in March 2002, when he was appointed CEO and Chairman. Marc managed the acquisition of Genset by Serono and became CEO and Chairman of Serono France Holding. Marc also served as the director of several biotechnology companies, and actively participated in advisory boards of several investment funds. Marc is the ‘father’ of Moleac: He came up with the disruptive idea of looking into Asian Traditional Medicine as a source of innovation for allopathic medicine, hence pioneering a novel route to drug development. He assembled the founding team and created Moleac in 2002. As a non-executive Chairman (2003-2013) of Moleac, Marc was present at every important moment of the company and contributed to making Moleac the successful company as it is today. Marc was gifted with many talents. He was a strong personality and a daring, creative and exceptional entrepreneur. His passion for science and strong business acumen, combined with amazing intuitions has shaped Moleac during its first decade, and will continue to be visible in the future. Marc often travelled to Singapore, and was even close to the day-to-day operations. |
|
His values, his communicable enthusiasm and optimism, his determination, his love for life and his curiosity strongly influenced the people who had the chance to work with him. Colleagues and friends describe him as a great visionary, who was a real expert in his field and inspired many with his ideas. For many today it is a privilege to have known Marc, describing him as the “great man”. Marc Vasseur will be missed enormously. We will continue to develop and grow Moleac based on the initial impulsions and strengths he gave us and stay true to the visions of the founders by meeting the needs of those who suffer. Our thoughts and prayers today go out to his family and friends.
|
|